BTK inhibitor

3 · 20 / page

Ask MedXY AI

Latest news

Tag

Hematology-OncologyABC-DLBCLBTK inhibitor

Targeting Ibrutinib Resistance Pathways with miR-28 in ABC-DLBCL

By MedXY|May 29, 2026

miR-28 suppresses the emergence of ibrutinib resistance in ABC-DLBCL by disrupting clonal selection and dampening mitochondrial and mTOR signaling, with promising preclinical nanoparticle delivery results.

Clinical UpdatesBTK inhibitorclinical trial

BTK inhibitor

Latest news

Targeting Ibrutinib Resistance Pathways with miR-28 in ABC-DLBCL

Fenebrutinib in Relapsing Multiple Sclerosis: New Evidence from the FENopta Phase 2 Trial

Pirtobrutinib Demonstrates Superior Efficacy and Tolerability in cBTKi-Pretreated CLL/SLL: Insights from the BRUIN CLL-321 Phase III Trial